JAP7 Rec'd PCT/PTO 17 APR 2006

OFE		<u>\</u>	ri kecara	PIREO T.	ATT ZOUB			
APR 1 7 2006	TRANSMITTAL LETTER (General - Patent Pending)			Docket No. NBG-109				
In Re Application of: Aldo Salimbeni et al.								
Application No. 10/537,731	Filing Date June 6, 2005	Examiner Unassigned	Customer No. 48388	Group Art Unit Unassigned	Confirmation No. 7958			
Title: PROCESS FOR THE PREPARATION OF BYCYLIC PEPTIDE COMPOUNDS								
COMMISSIONER FOR PATENTS:								
Transmitted herewith	n is:							
•		; 1 paper copy of Sequence Listition; postcard. Certificate of ma	•	•	redit Card			
in the above identified application.								
 A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. 12-2147 as described below. 								
Charge the amount of								
	☐ Credit any overpayment.							
	☐ Charge any additional fee required. ☐ Payment by credit card. Form PTO 2038 is attached.							
Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
	1		Dated: Apri	1 5, 2006				
	Signature							
Mark D. Lorusso LORUSSO & ASSOC	CIATES							
3 Pinecrest Terrace	, 20		I hereby certify	that this corres	pondence is being			
Portsmouth, NH 03801			deposited with the United States Postal Service with sufficient postage as first class mail in an envelope					
Tel.: 603-427-0070 Fax: 603-427-5530			addressed to the "Commissioner for Patents, P.O. Box					
Email: mlorusso@llip	law.com		1450, Alexandria Aptir 5, 2 (Oate)	, VA 22313-1450" [: 006	37 CFR 1.8(a)] on			

cc:

Signature of Person Mailing Correspondence

Mark D. Lorusso

Typed or Printed Name of Person Mailing Correspondence

ATTORNEY'S DOCKET NO.: NBG-109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Aldo Salimbeni et al.

Serial No.:

10/537,731

Filed:

June 6, 2005

For:

PROCESS FOR THE PREPARATION OF BICYCLIC

PEPTIDE COMPOUNDS

Examiner: Art Unit:

Not Assigned Not Assigned

CERTIFICATE OF MAILING

I hereby certify that the following correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313—1450 on April 5, 2006.

Mark D. Lorusso

Commissioner for Patents PO BOX 1450 Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

This responds to the Notification mailed October 6, 2005. Enclosed herewith are two copies of the Sequence Listing in computer readable format. Another copy of the Sequence Listing in paper form is also enclosed. The content of the Sequence Listing information recorded in computer readable form is identical to the written sequence listing and does not include any new matter.

Respectfully submitted,

Mark D. Lorusso

Reg. No. 41,955

Lorusso & Associates

3 Pinecrest Terrace

Portsmouth, NH 03801

Tel: (603) 427-0070 Attorneys for Applicants

Docket No.: NBG-109

Date: April 5, 2006



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PC Box 150 Vecambra, Vigena 2233-1450 view asploges

U.S. APPLICATION NUMBER NO FIRST NAMED APPLICANT ATTY, DOCKET NO. 10/537,731 Aldo Salimbeni NBG-109

EXTERNATIONAL APPLICATION NO

Lorusso & Loud 15 Rye Street 312 Portsmouth, NH 03801

PCT/EP03/13696 LA. FILING DATE PRIORITY DATE 12/04/2003 12/06/2002

CONFIRMATION NO. 7958 371 FORMALITIES LETTER *OC000000017174210*

Date Mailed: 10/06/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

Telephone: (703) 308-9140 EXT 212

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.				
10/537,731	PCT/EP03/13696	NBG-109				

FORM PCT/DO/EO/922 (371 Formalities Notice)